Shalvaree Vaidya1,2, Clare L Hibbert3, Elizabeth Kinter4, Stefan Boes3. 1. University of Lucerne, Frohburgstrasse 3, 6002, Lucerne, Switzerland. shalvaree.vaidya@stud.unilu.ch. 2. , Steinhofstrasse 15C, 6005, Lucerne, Switzerland. shalvaree.vaidya@stud.unilu.ch. 3. University of Lucerne, Frohburgstrasse 3, 6002, Lucerne, Switzerland. 4. European Market Access, Biogen International, Landis + Gyr-Strasse 3, 6300, Zug, Switzerland.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is an incurable, debilitating disease which impairs lung function and eventually leads to death. Currently, there is a lack of effective modifying therapies and treatments for IPF as the underlying epidemiological mechanism is not clearly understood. This leads to difficulty in diagnosing and managing IPF, which results in a high incurment of disease-associated cost. Even though IPF poses a substantial economic burden, there is a lack of research available on cost triggers and healthcare utilization, which can be a barrier to future economic evaluations of new medicines for IPF. OBJECTIVES: We aimed to conduct a systematic literature review (SLR) to identify the key cost-generating events of IPF and to gather any related costing information. RESULTS: The data showed that the main events triggering high resource use in patients were the symptoms of IPF progression along with comorbidities and lung transplantations. These events result in a high economic impact through the use of medications, health care professionals, and hospital stays. CONCLUSION: More research is needed to identify the direct, and indirect, relationships between IPF events and the costs they generate. This would help to further evaluate the area of need for future health technologies and to understand what events should be targeted to reduce the global economic burden of IPF.
BACKGROUND:Idiopathic pulmonary fibrosis (IPF) is an incurable, debilitating disease which impairs lung function and eventually leads to death. Currently, there is a lack of effective modifying therapies and treatments for IPF as the underlying epidemiological mechanism is not clearly understood. This leads to difficulty in diagnosing and managing IPF, which results in a high incurment of disease-associated cost. Even though IPF poses a substantial economic burden, there is a lack of research available on cost triggers and healthcare utilization, which can be a barrier to future economic evaluations of new medicines for IPF. OBJECTIVES: We aimed to conduct a systematic literature review (SLR) to identify the key cost-generating events of IPF and to gather any related costing information. RESULTS: The data showed that the main events triggering high resource use in patients were the symptoms of IPF progression along with comorbidities and lung transplantations. These events result in a high economic impact through the use of medications, health care professionals, and hospital stays. CONCLUSION: More research is needed to identify the direct, and indirect, relationships between IPF events and the costs they generate. This would help to further evaluate the area of need for future health technologies and to understand what events should be targeted to reduce the global economic burden of IPF.
Authors: Emma Loveman; Vicky R Copley; Jill L Colquitt; David A Scott; Andy J Clegg; Jeremy Jones; Katherine M A O'Reilly; Sally Singh; Claudia Bausewein; Athol Wells Journal: BMC Pharmacol Toxicol Date: 2014-11-19 Impact factor: 2.483
Authors: Edward C F Wilson; Ludmila Shulgina; Anthony P Cahn; Edwin R Chilvers; Helen Parfrey; Allan B Clark; Orion P Twentyman; Andrew M Wilson Journal: Pharmacoeconomics Date: 2014-01 Impact factor: 4.981
Authors: Andrew J Bryant; Vinayak Shenoy; Chunhua Fu; George Marek; Kyle J Lorentsen; Erica L Herzog; Mark L Brantly; Dorina Avram; Edward W Scott Journal: Am J Respir Cell Mol Biol Date: 2018-02 Impact factor: 6.914
Authors: Nils Hoyer; Laura H Thomsen; Mathilde M W Wille; Torgny Wilcke; Asger Dirksen; Jesper H Pedersen; Zaigham Saghir; Haseem Ashraf; Saher B Shaker Journal: BMC Pulm Med Date: 2020-03-19 Impact factor: 3.317
Authors: Phillen Nozibuyiso Maqhuzu; Michael Kreuter; Thomas Bahmer; Nicolas Kahn; Martin Claussen; Rolf Holle; Larissa Schwarzkopf Journal: Respir Res Date: 2021-08-03